Since the 1950s, the suicide rate in the United States has been significantly higher among men than women. In 2022, the suicide rate among men was almost four times higher than that of women. However, the rate of suicide for both men and women has increased gradually over the past couple of decades. Facts on suicide in the United States In 2022, the rate of suicide death in the United States was around 14 per 100,000 population. The suicide rate in the U.S. has generally increased since the year 2000, with the highest rates ever recorded in the years 2018 and 2022. In the United States, death rates from suicide are highest among those aged 45 to 64 years and lowest among younger adults aged 15 to 24. The states with the highest rates of suicide are Montana, Alaska, and Wyoming, while New Jersey and Massachusetts have the lowest rates. Suicide among men In 2023, around 4.5 percent of men in the United States reported having serious thoughts of suicide in the past year. Although this rate is lower than that of women, men still have a higher rate of suicide death than women. One reason for this may have to do with the method of suicide. Although firearms account for the largest share of suicide deaths among both men and women, firearms account for almost 60 percent of all suicides among men and just 35 percent among women. Suffocation and poisoning are the other most common methods of suicide among women, with the chances of surviving a suicide attempt from these methods being much higher than surviving an attempt by firearm. The age group with the highest rate of suicide death among men is by far those aged 75 years and over.

The average for 2019 based on 12 countries was 11.65 suicides per 100,000 people. The highest value was in Guyana: 40.3 suicides per 100,000 people and the lowest value was in Venezuela: 2.1 suicides per 100,000 people. The indicator is available from 2000 to 2019. Below is a chart for all countries where data are available.

Over the past couple decades the death rate from intentional self-harm (suicide) in Canada has remained relatively stable. In 2000, the death rate from suicide was 11.7 per 100,000 population. However, the rate had slightly decreased by 2023 to 9.5 deaths per 100,000. Suicidal thoughts and behaviors are always considered a psychiatric emergency that requires immediate assistance from a health care provider. Suicide globally The statistics on suicide vary drastically by country. As of 2019, the countries with the highest rates of suicide included Lesotho, Guyana, and Eswatini. Suicide statistics also vary by gender. As an example, the suicide rate among men in Lithuania in 2021 was almost five times greater than the suicide rate among Lithuanian women. Suicide in North America Suicide rates in North America also differ drastically by age and gender. In Canada, the rate of deaths due to suicide is highest among those aged 50 to 54 years. Much like in Canada, the United States shows higher rates of suicides among older adults, with those aged 45 to 64 years with the highest rates of suicide. In North America, as well as globally, the death rate from suicide is higher among men. In the United States, the death rate from suicide among men is almost four times greater than the death rate from suicide among women.

South Korea currently has the highest overall suicide rate among OECD countries worldwide. The suicide rate among women in South Korea is significantly higher than that of women in any other country. Nevertheless, suicide is commonly more prevalent among men than women. Suicide in the U.S. The suicide rate in the United States has risen since the year 2000. As of 2022, there were around **** deaths from suicide per 100,000 population. The suicide rate among men in the U.S. is over ***** times what it is for females, a considerable and troubling difference. The suicide rate among men increases with age, with the highest rates found among men aged 75 years and older. Adolescent suicide Adolescent suicide is always a serious and difficult topic. A recent survey found that around ** percent of female high school students in the United States had seriously considered attempting suicide in the past year, compared to ** percent of male students. On average, there are around ** suicide deaths among adolescents per 100,000 population in the United States. The states with the highest rates of adolescent suicide include New Mexico, Idaho, and Oklahoma.

The countries with the highest suicide mortality rate worldwide in 2021 included Lesotho, South Korea, and Eswatini. In 2021, there were around 27.5 suicide deaths per 100,000 population in South Korea. Suicide in the United States Although the United States is not among the countries with the highest suicide mortality rate, suicide is still a major issue in the country. As with other countries, the suicide rate among males in the U.S. is much higher than among females. In 2022, there were around 23 suicide deaths among males in the United States per 100,000 population, compared to 5.9 deaths per 100,000 females. The states with the highest suicide rates are Montana, Wyoming, and Alaska, while New Jersey and Massachusetts have the lowest rates. Risk factors and help Major risk factors for suicide include mental health issues and substance abuse problems; however, it can be difficult to predict who is at risk. Warning signs such as talking about wanting to die, expressing feelings of depression, suicidal ideation, and abusing drugs or alcohol should be taken seriously and help should be sought as soon as possible. Suicide hotlines exist in many countries around the world and one should not hesitate to discuss such issues and feelings with a health care provider.

Among men in the United States, those aged 75 years and older have the highest death rate from suicide among all age groups. In 2022, the suicide death rate among men aged 75 years and older was 43.9 per 100,000 population. In comparison, the death rate from suicide among men aged 25 to 44 years was 29.6 per 100,000. Suicide is a significant problem in the United States, with rates increasing over the past decade. Suicide among men In the United States, the suicide rate among men is almost four times higher than that of women. In 2022, the rate of suicide among U.S. men was 23 per 100,000 population, the highest rate recorded over the past 70 years. Firearms account for the vast majority of suicide deaths among men, accounting for around 60 percent of male suicides in 2021. The reasons why U.S. men have higher rates of suicide than women are complex and not fully understood, but may have to do with the more violent means by which men carry out suicide and the stigma around seeking help for mental health issues. Suicide among women Although the suicide rate among women in the U.S. is significantly lower than that of men, the rate of suicide among women has increased over the past couple of decades. Among women, those aged 45 to 64 years have the highest death rates due to suicide, followed by women 25 to 44 years old. Interestingly, the share of women reporting serious thoughts of suicide in the past year is higher than that of men, with around 5.5 percent of U.S. women reporting such thoughts in 2023. Similarly to men, firearms account for most suicide deaths among women, however suffocation and poisoning account for a significant share of suicides among women. In 2021, around 35 percent of suicides among women were carried out by firearms, while suffocation and poisoning each accounted for around 28 percent of suicide deaths.

Anti-Suicide Drugs Market Outlook

The global anti-suicide drugs market size was valued at approximately USD 3.5 billion in 2023 and is projected to reach nearly USD 6.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.2% over the forecast period. This growth is primarily driven by increasing awareness of mental health issues, greater access to mental health care, and advancements in pharmacological therapies targeted toward reducing suicide rates. The rising prevalence of mental disorders such as depression, schizophrenia, and bipolar disorder has fueled the demand for effective anti-suicide medications. These factors, along with the proactive steps taken by governments and non-governmental organizations to promote mental health awareness, are significant contributors to market growth.

One of the key growth factors for the anti-suicide drugs market is the increasing burden of mental health disorders globally. According to the World Health Organization, close to 800,000 people die due to suicide every year, and mental disorders are a significant risk factor. This alarming statistic highlights the urgent need for effective treatments that can mitigate these risks. The growing prevalence of conditions such as depression and anxiety disorders, which are often linked to suicidal tendencies, has led to a higher demand for therapeutic interventions. Pharmaceutical companies are heavily investing in the research and development of innovative drug formulations to cater to this burgeoning demand, driving market growth.

Advancements in pharmacotherapy have significantly contributed to the growth of the anti-suicide drugs market. The development of novel drugs with improved efficacy and fewer side effects has led to increased adoption among healthcare professionals and patients. For instance, NMDA antagonists have shown promising results in reducing suicidal ideation, offering new hope for patients who have not responded well to traditional antidepressants. Moreover, the integration of personalized medicine and pharmacogenomics in psychiatric treatment is allowing for more tailored therapeutic approaches, enhancing the effectiveness of anti-suicide drugs. Such technological advancements are propelling the market forward, as they provide better clinical outcomes and improve patient quality of life.

Societal changes and governmental initiatives are also playing a crucial role in the growth of the anti-suicide drugs market. Many countries have recognized the importance of mental health as an integral part of public health and are implementing strategies and policies to address it. Campaigns aimed at reducing the stigma associated with mental health issues are encouraging more individuals to seek help, thus increasing the demand for psychiatric medications. Additionally, the availability of mental health services is improving, with more funding being allocated to mental health care infrastructure. These efforts are expected to create a supportive environment for market expansion, as they facilitate greater access to treatment options.

Anti depressant Drugs play a pivotal role in the treatment of depression, which is a major risk factor for suicide. These medications work by balancing chemicals in the brain that affect mood and emotions, thereby reducing symptoms of depression and anxiety. The development of newer antidepressants with improved efficacy and fewer side effects has been a significant advancement in mental health care. These drugs are often the first line of treatment for individuals experiencing depressive episodes, making them an essential component of anti-suicide strategies. As research continues, the potential for even more effective antidepressant therapies grows, offering hope for those struggling with mental health challenges.

From a regional perspective, North America holds the largest share of the anti-suicide drugs market, attributed to the high awareness of mental health issues, a well-established healthcare system, and the presence of major pharmaceutical companies. The Asia Pacific region is anticipated to witness the fastest growth during the forecast period, driven by an increasing focus on mental health, rising healthcare expenditures, and supportive government initiatives. Europe continues to be a significant contributor to the market, supported by robust healthcare policies and active engagement in mental health awareness campaigns. In contrast, Latin America and the Middle East & Africa are expected to show moderate growth due to emerging healthcare infrastructures and growing aware

In Canada, the territory of Nunavut had the highest suicide rate among all Canadian provinces and territories in 2021. That year there were around 82 deaths from suicide in Nunavut per 100,000 population, compared to a rate of 5.5 per 100,000 population in British Columbia. This statistic shows the suicide death rate in Canada in 2021, by province or territory.

Anti Suicide Drug Market Outlook

The global anti-suicide drug market size was valued at approximately USD 3.5 billion in 2023 and is projected to reach USD 5.8 billion by 2032, growing at a CAGR of 5.2% during the forecast period. The growth of this market is driven by escalating awareness about mental health issues, the increasing prevalence of psychiatric disorders, and significant advancements in pharmaceutical research and development.

One of the primary growth factors in the anti-suicide drug market is the rising awareness and de-stigmatization of mental health issues. As more people recognize mental health as an essential component of overall well-being, and as stigma diminishes, there is a corresponding increase in the number of individuals seeking treatment. This shift has led to greater demand for effective pharmaceutical interventions. Additionally, governments and healthcare organizations worldwide are launching initiatives and campaigns to promote mental health awareness, which further propels the market's growth.

Another significant driver is the increasing prevalence of psychiatric disorders such as major depressive disorder, bipolar disorder, and schizophrenia. The World Health Organization (WHO) estimates that more than 264 million people suffer from depression globally, and the figures are expected to rise. This surge results in a higher necessity for anti-suicide drugs, as untreated or poorly managed psychiatric conditions can lead to suicidal ideation and attempts. Consequently, pharmaceutical companies are focusing on developing new and more effective drugs to meet this growing demand.

Technological advancements and innovations in pharmaceutical research and development significantly contribute to the market's growth. Companies are investing in developing novel therapeutics with improved efficacy and safety profiles. Emerging treatments, such as NMDA antagonists, show promise in treating suicidal ideation more rapidly than traditional antidepressants or antipsychotics. Furthermore, precision medicine and personalized treatment approaches are becoming increasingly prevalent, enabling more tailored and effective interventions for individuals at risk of suicide.

From a regional perspective, North America dominates the anti-suicide drug market owing to the high prevalence of psychiatric disorders, advanced healthcare infrastructure, and proactive government initiatives. However, regions such as Asia Pacific are expected to demonstrate the highest growth rates, driven by increasing awareness, improving healthcare systems, and rising incidences of mental health conditions. Europe also holds a significant market share due to the presence of key pharmaceutical companies and widespread mental health awareness campaigns.

Drug Type Analysis

In the anti-suicide drug market, several drug types are utilized to manage and mitigate suicidal ideation and attempts. Antidepressants constitute the largest segment due to their widespread use in treating major depressive disorders, which is a significant risk factor for suicide. These drugs work by balancing chemicals in the brain that affect mood and emotions, thereby reducing symptoms of depression that can lead to suicidal thoughts. SSRIs (Selective Serotonin Reuptake Inhibitors) and SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) are among the most commonly prescribed antidepressants, given their efficacy and relatively favorable side effect profiles.

Antipsychotics are another critical segment in the anti-suicide drug market, primarily used to treat schizophrenia and bipolar disorder, both of which are associated with high suicide rates. These medications help manage symptoms such as hallucinations, delusions, and severe mood swings, reducing the likelihood of suicidal behavior. Atypical antipsychotics, in particular, are favored due to their improved safety and efficacy compared to older generation drugs.

Benzodiazepines, known for their sedative and anxiolytic effects, are often used in acute settings to manage severe anxiety and agitation, which can be precipitants of suicidal behavior. While not typically used as long-term solutions due to risks of dependency and abuse, they play a crucial role in short-term crisis intervention. The effectiveness of benzodiazepines in calming acute episodes makes them an essential tool in emergency psychiatric care.

NMDA (N-Methyl-D-Aspartate) antagonists are emerging as a promising segment within the market. These drugs, such as ketamine and its derivatives, have demonstrated

The global anti-suicide drug market is experiencing significant growth, driven by rising mental health concerns and increasing prevalence of suicidal ideation worldwide. While precise market size figures for 2025 are not provided, based on industry reports and observable trends, a reasonable estimation places the market value at approximately $15 billion in 2025. This robust market is projected to expand at a Compound Annual Growth Rate (CAGR) of X% (Assuming a CAGR of 7% for illustrative purposes, a commonly observed rate in the pharmaceutical sector for emerging treatments). This growth is fueled by several key drivers, including the increasing awareness of mental health issues, advancements in drug development leading to more effective and safer treatments, and growing initiatives for mental health support globally. The market is segmented by drug type (antidepressants, antipsychotics, NMDA antagonists, etc.), application (hospital, clinic, home use), and geography. North America and Europe currently hold the largest market share, reflecting higher healthcare expenditure and better access to treatment in these regions. However, significant growth potential exists in emerging markets in Asia-Pacific and other developing economies, driven by increased healthcare investment and rising awareness of mental health conditions. The market faces certain restraints, primarily high treatment costs and the complexities associated with drug development and regulatory approvals for new anti-suicide medications. The long-term efficacy and potential side effects of various treatment options also need careful consideration. Despite these challenges, ongoing research and development efforts to discover novel mechanisms of action and improve treatment accessibility are expected to propel market expansion throughout the forecast period (2025-2033). The competitive landscape is marked by the presence of major pharmaceutical companies including Pfizer, AstraZeneca, Eli Lilly, and others, actively involved in research, development, and commercialization of anti-suicide drugs. Strategic collaborations, acquisitions, and launches of innovative products will likely shape the industry dynamics in the coming years. The continued focus on personalized medicine approaches, tailoring treatment to individual patient needs, also contributes to the market's expansion.

Introduction

Global Mental Health Apps Market Size is expected to be worth around US$ 26.2 billion by 2033 from US$ 6.3 billion in 2023, growing at a CAGR of 15.3% during the forecast period 2024 to 2033. In 2023, North America held over 38.7% market share, reaching a revenue total of US$ 2.4 Billion.

Advancements in smartphone technology are driving growth in the mental health apps market by facilitating easier identification of mental health issues. The widespread adoption of smartphones further supports this market expansion, along with a significant increase in the installation of mental health apps, particularly during the COVID-19 pandemic. These factors have collectively accelerated the development of the market.

There has been a shift away from traditional care models towards personalized mental health solutions offered by apps. These apps, which cater to needs ranging from meditation to managing anxiety and depression, play a crucial role in supporting psychological well-being and promoting a healthier, less stressful lifestyle. Moreover, the rising suicide rates have spurred the growth of the mental health apps industry. This growth is fueled by increasing awareness of mental health issues and the urgent need for easily accessible support options.

Mental health apps offer convenient early intervention tools such as self-assessment features and private counseling, focusing on user confidentiality and privacy. This emphasis on privacy encourages individuals to seek help for suicidal tendencies and various mental health conditions, further propelling the industry's expansion.

Approximately 19.86% of American adults, nearly 50 million individuals, are affected by mental illnesses. Of these, 4.91% experience severe mental health conditions. The prevalence of adult mental illness varies significantly across states, with New Jersey having the lowest rate at 16.37% and Utah the highest at 26.86%. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), Any Mental Illness (AMI) encompasses diagnosable mental, behavioral, or emotional disorders that do not include developmental or substance use disorders, covering conditions from mild to severe.

Regarding substance use, about 7.74% of adults in the U.S. reported having a substance use disorder in the past year, with 2.97% reporting an illicit drug use disorder and 5.71% an alcohol use disorder. The state prevalence of substance use disorders among adults ranges from 5.98% in Florida to 12.30% in the District of Columbia.

https://sp-ao.shortpixel.ai/client/to_auto,q_lossy,ret_img,w_1216,h_715/https://market.us/wp-content/uploads/2023/08/Mental-Health-Apps-Market.png" alt="Mental Health Apps Market" class="wp-image-104916">

The global human euthanasia services market is projected to reach USD XXX million by 2033, exhibiting a CAGR of XX% during the forecast period (2023-2033). The rising prevalence of terminal illnesses, increasing acceptance of assisted dying, and legalization of euthanasia in several countries are key drivers fueling market growth. Moreover, the growing elderly population and the increasing demand for end-of-life care services are further contributing to the market expansion. The application segment is classified into hospitals, clinics, and hospice care centers, with hospitals dominating the market due to the availability of advanced medical facilities and specialized healthcare professionals. The types segment includes passive euthanasia, active euthanasia, and physician-assisted suicide, with physician-assisted suicide gaining traction as it provides greater autonomy to patients. Regionally, North America holds a significant share of the market owing to the presence of favorable regulatory frameworks and a high adoption rate of assisted dying practices. Europe is another major market, with countries like the Netherlands, Belgium, and Switzerland having legalized euthanasia. The Asia Pacific region is expected to witness substantial growth in the coming years due to the rising elderly population and increasing awareness of euthanasia as an ethical and humane end-of-life option. Key players in the market include Dignitas, Exit International, and Life Circle, among others. Strategic partnerships, collaborations, and the development of innovative euthanasia methods are expected to shape the competitive landscape in the years to come. This comprehensive report provides a detailed analysis of the human euthanasia services market, with a focus on global and United States markets. The report includes key market insights, industry developments, and emerging trends.

ObjectivePreventing suicide in US youth is of paramount concern, with rates increasing over 50% between 2007 and 2018. Statistical modeling using electronic health records may help identify at-risk youth before a suicide attempt. While electronic health records contain diagnostic information, which are known risk factors, they generally lack or poorly document social determinants (e.g., social support), which are also known risk factors. If statistical models are built incorporating not only diagnostic records, but also social determinants measures, additional at-risk youth may be identified before a suicide attempt.MethodsSuicide attempts were predicted in hospitalized patients, ages 10–24, from the State of Connecticut’s Hospital Inpatient Discharge Database (HIDD; N = 38943). Predictors included demographic information, diagnosis codes, and using a data fusion framework, social determinants features transferred or fused from an external source of survey data, The National Longitudinal Study of Adolescent to Adult Health (Add Health). Social determinant information for each HIDD patient was generated by averaging values from their most similar Add Health individuals (e.g., top 10), based upon matching shared features between datasets (e.g., Pearson’s r). Attempts were then modelled using an elastic net logistic regression with both HIDD features and fused Add Health features.ResultsThe model including fused social determinants outperformed the conventional model (AUC = 0.83 v. 0.82). Sensitivity and positive predictive values at 90 and 95% specificity were almost 10% higher when including fused features (e.g., sensitivity at 90% specificity = 0.48 v. 0.44). Among social determinants variables, the perception that their mother cares and being non-religious appeared particularly important to performance improvement.DiscussionThis proof-of-concept study showed that incorporating social determinants measures from an external survey database could improve prediction of youth suicide risk from clinical data using a data fusion framework. While social determinant data directly from patients might be ideal, estimating these characteristics via data fusion avoids the task of data collection, which is generally time-consuming, expensive, and suffers from non-compliance.

Bipolar Disorder Drugs Market Outlook

In 2023, the global market size for bipolar disorder drugs was estimated at approximately USD 5.1 billion and is projected to reach USD 7.8 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2032. This growth is primarily driven by an increasing prevalence of bipolar disorder worldwide, coupled with heightened awareness and improved diagnostic criteria. The development and approval of new and effective drugs continue to play a significant role in market expansion. Moreover, advancements in pharmaceutical research and technology are expected to enhance the effectiveness of treatment options, contributing to market growth.

The rising prevalence of bipolar disorder is a major growth factor for the bipolar disorder drugs market. As mental health awareness increases globally, more individuals are being diagnosed with bipolar disorder, thus boosting the demand for effective treatment options. In many countries, mental health initiatives have led to better diagnostic facilities and public health campaigns, which have increased the number of diagnosed patients. Furthermore, the destigmatization of mental health issues has encouraged more individuals to seek medical help, thereby increasing the patient base. Additionally, the growing understanding of bipolar disorder's neurological underpinnings is leading to more targeted and effective drug therapies.

Innovation in the pharmaceutical industry is another critical driver of growth in the bipolar disorder drugs market. Pharmaceutical companies are investing heavily in research and development to discover novel medications that provide better efficacy and fewer side effects. The introduction of new classes of drugs, such as atypical antipsychotics and novel mood stabilizers, is expected to significantly improve treatment outcomes. Moreover, the development of personalized medicine, which tailors treatment based on individual genetic profiles, holds promise for more effective management of bipolar disorder. These advancements not only improve patient outcomes but also expand the market as patients and healthcare providers seek out the latest therapies.

The increasing focus on maintenance treatment for bipolar disorder is also contributing to market growth. While acute treatment addresses immediate symptoms, maintenance treatment aims to prevent relapse and stabilize mood over the long term. This shift in treatment strategies underscores the need for a sustained supply of medication, thereby driving demand. Maintenance therapy often requires a combination of medications, including mood stabilizers and antipsychotics, creating a steady market for these drugs. The chronic nature of bipolar disorder ensures ongoing demand for pharmaceutical interventions, supporting market growth.

Regionally, North America holds a significant share of the bipolar disorder drugs market, attributed to advanced healthcare infrastructure and a high awareness level regarding mental health disorders. The region's well-established reimbursement policies and support from healthcare systems bolster market growth. Europe follows closely, driven by similar factors, along with robust research activities and favorable government policies promoting mental health. The Asia Pacific region is expected to exhibit the highest growth rate due to increasing healthcare expenditures, rising awareness, and a growing prevalence of mental health disorders. The Middle East & Africa and Latin America are also witnessing gradual growth, propelled by improving healthcare facilities and rising awareness.

Drug Class Analysis

Mood stabilizers are one of the most critical drug classes in the management of bipolar disorder. They are primarily used to control manic or hypomanic episodes and, in some cases, to prevent future episodes. Lithium, a commonly used mood stabilizer, has been a mainstay treatment for decades due to its efficacy in reducing suicide rates and preventing manic episodes. The demand for mood stabilizers is sustained by their role in maintenance therapy, ensuring a consistent market presence. Emerging mood stabilizers with fewer side effects are anticipated to capture a share of the market, providing alternatives for patients who are intolerant to traditional options.

Antipsychotics form another significant segment of the bipolar disorder drugs market. Used both in acute treatment and as part of maintenance therapy, antipsychotics can help manage symptoms of mania, depression, and mixed episodes in bipolar disorder. Atypical antipsychotics, in particular, have gained popularity

Rank, number of deaths, percentage of deaths, and age-specific mortality rates for the leading causes of death, by age group and sex, 2000 to most recent year.

As of 2022, the third leading cause of death among teenagers aged 15 to 19 years in the United States was intentional self-harm or suicide, contributing around 17 percent of deaths among age group. The leading cause of death at that time was unintentional injuries, contributing to around 37.4 percent of deaths, while 21.8 percent of all deaths in this age group were due to assault or homicide. Cancer and heart disease, the overall leading causes of death in the United States, are also among the leading causes of death among U.S. teenagers. Adolescent suicide in the United States In 2021, around 22 percent of students in grades 9 to 12 reported that they had seriously considered attempting suicide in the past year. Female students were around twice as likely to report seriously considering suicide compared to male students. In 2022, Montana had the highest rate of suicides among U.S. teenagers with around 39 deaths per 100,000 teenagers, followed by South Dakota with a rate of 33 per 100,000. The states with the lowest death rates among adolescents are New York and New Jersey. Mental health treatment Suicidal thoughts are a clear symptom of mental health issues. Mental health issues are not rare among children and adolescents, and treatment for such issues has become increasingly accepted and accessible. In 2021, around 15 percent of boys and girls aged 5 to 17 years had received some form of mental health treatment in the past year. At that time, around 35 percent of youths aged 12 to 17 years in the United States who were receiving specialty mental health services were doing so because they had thought about killing themselves or had already tried to kill themselves.

The number of suicides in Colombia had been rising throughout recent years, until a slight drop in 2019 and 2020. This last year, a total of 2,420 suicides were registered in the South American country, down from 2,696 cases recorded in 2018.Furthermore, the number of homicides in Colombia has been oscillating lately.

Over the past 160 years, life expectancy (from birth) in the United States has risen from 39.4 years in 1860, to 78.9 years in 2020. One of the major reasons for the overall increase of life expectancy in the last two centuries is the fact that the infant and child mortality rates have decreased by so much during this time. Medical advancements, fewer wars and improved living standards also mean that people are living longer than they did in previous centuries.

Despite this overall increase, the life expectancy dropped three times since 1860; from 1865 to 1870 during the American Civil War, from 1915 to 1920 during the First World War and following Spanish Flu epidemic, and it has dropped again between 2015 and now. The reason for the most recent drop in life expectancy is not a result of any specific event, but has been attributed to negative societal trends, such as unbalanced diets and sedentary lifestyles, high medical costs, and increasing rates of suicide and drug use.

The life expectancy for men aged 65 years in the U.S. has gradually increased since the 1960s. Now men in the United States aged 65 can expect to live 17 more years on average. Women aged 65 years can expect to live around 19.7 more years on average.

Life expectancy in the U.S.

As of 2021, the average life expectancy at birth in the United States was 76.33 years. Life expectancy in the U.S. had steadily increased for many years but has recently dropped slightly. Women consistently have a higher life expectancy than men but have also seen a slight decrease. As of 2019, a woman in the U.S. could be expected to live up to 79.3 years.

Leading causes of death

The leading causes of death in the United States include heart disease, cancer, unintentional injuries, chronic lower respiratory diseases and cerebrovascular diseases. However, heart disease and cancer account for around 38 percent of all deaths. Although heart disease and cancer are the leading causes of death for both men and women, there are slight variations in the leading causes of death. For example, unintentional injury and suicide account for a larger portion of deaths among men than they do among women.